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Cairo, EgyptA B S T R A C TBackground: The combination of antiplatelet and anticoagulant ther-
apy signiﬁcantly reduces the rate of thromboembolic events in patients
with heart valves compared with anticoagulant therapy alone. Cost-
effectiveness of this therapy in Egypt, however, has not yet been
established. Objective: The aim of the present study was to evaluate
the cost-effectiveness of the combined use of warfarin and low-dose
aspirin (100 mg) versus warfarin alone in patients with mechanical
aortic heart valve prostheses who began therapy at the age of 50 to 60
years over a 5-year period from the perspective of the medical
providers. Methods: A cohort Markov process model with ﬁve health
states (recovery, reoperation, bleeding, thromboembolism, and death)
based on Egyptian clinical practice was derived from published sources.
The clinical parameters were derived from meta-analyses of random-
ized controlled trials of patients with mechanical valve prostheses. The
quality of life of the health states was derived using the available
published data. Direct medical costs were obtained from four top-rated
governmental cardiology hospitals in Egypt. All costs and effects were
discounted at 3.5% annually. All costs were converted using the
purchasing power parity rate and are reported in US $ for the ﬁnancial
year of 2013. Results: The total quality-adjusted life-years (QALYs)
were estimated to be 1.1616 and 1.1199 for the warfarin plus
aspirin group and the warfarin group, respectively, which resulted inee front matter Copyright & 2014, International S
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ypt.a difference of 0.0416 QALYs. The total costs for the warfarin plus
aspirin group and the warfarin group were US $307.33 and US $315.25,
respectively (the difference was US $7.92), which yielded an incremen-
tal cost-effectiveness ratio of 190.38 for the warfarin plus aspirin
group. Thus, the combined therapy was dominant. Various one-way
sensitivity analyses indicated that probabilities of reoperation and
bleeding in the recovery state had the greatest effects on incremental
costs. The model parameters that had the greatest effects on incre-
mental QALYs were the relative risk reduction of death and the utility
value in the recovery state. Conclusions: The present study is the ﬁrst
cost-utility analysis to conclude that, from the perspective of Egyptian
medical providers, combined therapy is more effective and less costly
than warfarin alone for patients with mechanical aortic valve prosthe-
ses. For clinicians and patients who choose to focus on minimizing
thromboembolic risk, these results suggest that combined therapy
offers the best protection. This study helps to inform decisions about
the allocation of health care system resources and to achieve better
health in the Egyptian population.
Keywords: aortic valve replacement, aspirin, cost-effectiveness, Egypt,
warfarin.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In developing countries, one of the major causes of valvular heart
disease that requires valve replacement is rheumatic fever
affecting young adults [1]. In Africa, the combination of a lack
of resources, a lack of infrastructure, political, social, and eco-
nomic instability, poverty, overcrowding, and malnutrition con-
tributes to the persistence of the high burden of rheumaticvalvular heart, which later requires surgery [2]. Although
mechanical prostheses have excellent durabilities, they require
lifelong anticoagulation therapy to minimize risks of thrombosis
and embolism. Warfarin therapy reduces disability and fatal
thromboembolic events, but it can also cause disabling and fatal
hemorrhagic events. Anticoagulants without antiplatelet agents
do not provide adequate protection for patients with mechanical
aortic heart valve prostheses [3,4]. The addition of aspirin (80–160mgociety for Pharmacoeconomics and Outcomes Research (ISPOR).
conﬂicts of interest with regard to the content of this article.
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olism and valve thrombosis [5,6].
The initiation of an effective early antithrombotic therapy is
important because of its potential effect on the rate of early
thromboembolic complications after mechanical aortic heart
valve implantation [7,8]. An important question that remains to
be answered is whether the combined use of warfarin and low-
dose aspirin is more cost-effective than warfarin alone in Egyp-
tian governmental hospitals from the perspective of medical
providers. This question is particularly important because a
misconception exists in the Egyptian medical community that
the added clinical beneﬁt of reducing the risk of complications is
not worth the cost. Decision analysis is a quantitative method for
synthesizing data from numerous sources for the evaluation of
treatment alternatives and was developed to determine the cost-
effectiveness of the combined use of warfarin and low-dose
aspirin as compared with warfarin only.Objective
The objective of this study was to evaluate, from the perspective
of the medical provider, over a 5-year period, the cost-
effectiveness of the combined use of warfarin and 100-mg aspirin
compared with that of warfarin alone in patients with mechan-
ical aortic heart valve prostheses who began therapy between the
ages of 50 and 60 years.Methods
A half-cycle corrected Markov cohort process model with the ﬁve
mutually exclusive health states (recovery, reoperation, bleeding,
thromboembolism, and death) was developed (Fig. 1). The struc-
ture of this model reﬂects the natural history of the disease, the
current treatment practices, and the published studies in this
disease area [9]. This type of decision model is used for analyzing
clinical problems involving risks that change or occur repeatedly
over time [10]. The ﬁve identiﬁed health states of the model
structure correspond to the real practice of patient management
in Egypt and remain as simple as possible. The health states
(i.e., model contents) were validated by clinical experts and the data
that were available from the authors’ institutions. The model was
built to reﬂect patients who began therapy between the ages of 50
and 60 years. Although aortic valve replacement (AVR) can be
done at any age, it is most commonly done in patients 45 years
and older. A time horizon of 5 years was selected to reﬂect the
long-term consequences of the decisions. To simplify the model,
it was adapted to exclude clinical events that were not expected
to differ across the compared patients [11] (e.g., perioperative
mortality due to primary AVR and prosthetic valve endocarditis);Fig. 1 – Markov state-transition diagram. Not shown are the
transitions to the death state. B, bleeding; R, reoperation;
T, thromboembolism.however, the valve-related excess mortality rate described below
was included. The combined use of adjusted-dose warfarin and
100-mg oral aspirin (international normalized ratio 2–3) was
compared with the use of adjusted-dose warfarin (international
normalized ratio 2–3) alone, which is the currently recommended
practice. The transition probabilities from the recovery health
state to the reoperation, bleeding, thromboembolism, and death
states were derived from previously published sources [9,12].
A comprehensive search of PubMed and MEDLINE was con-
ducted for English articles published between 1985 and June 2013
to retrieve the available published data regarding the probabilities
of the health states, the relative risks of the combination therapy,
and the quality of life in the health states. Randomized controlled
trials (RCTs), systematic reviews, and meta-analyses of RCTs were
chosen because they provide the least biased and most robust
evidence regarding treatment. When RCTs were not available,
observational studies were included after considering expert
opinions regarding the synthesis of the clinical evidence. Articles
that addressed the long-term management of patients with
prosthetic heart valves were selected on the basis of terms related
to the clinical conditions and the cost-effectiveness of the combi-
nation; these terms included the following: “cost-effectiveness,”
“aortic valve replacement,” “antithrombotic,” “antiplatelet,” “anti-
coagulation,” “aspirin,” “vitamin K antagonist,” “warfarin,”
“thrombosis,” “bleeding,” “randomized controlled trial,” “random-
ized,” “controlled trial,” “meta-analysis,” and “systematic review.”
Articles that exclusively included trials that focused on elderly
patients were excluded because these trials evaluated a different
patient population. Twenty-two relevant articles were identiﬁed
by this electronic search and were reviewed, and six articles were
excluded for the above-mentioned reasons.
The cycle length of the model was 1 month to allow for a
precise estimation of the timing of events and related costs
because patients are unlikely to experience more than one major
event during this time [13]. This study adopted the perspective of
a medical provider seeking to maximize the health gains of the
population while representing the most efﬁcient use of the ﬁnite
resources available to Egyptian governmental hospitals [11]. All
costs and effects were discounted at 3.5% annually as recom-
mended by Egyptian guidelines [11].
Clinical Parameters
The following ﬁve health states were studied: the recovery state,
which was deﬁned by the patients being alive without event or
recovering after an event; reoperation, which was deﬁned by
patients undergoing reoperation or suffering operative morbidity;
bleeding, which was deﬁned by the requirement of hospital-
ization or blood transfusion for a major bleeding event; throm-
boembolism, which was deﬁned by the patients suffering a
thromboembolic event with morbidity; and death, which was
deﬁned as death from any cause. All patients who underwent the
indexed surgery without morbidity were initially deﬁned as being
in the recovery state. Thus, with every cycle, the patients who
survived the index surgery could remain in their current health
state or could experience the following: bleeding (fatal or non-
fatal), valve thrombosis followed by reoperation (fatal or non-
fatal), thromboembolism, or death from any cause.
Several assumptions were incorporated to simplify the model.
First, the population was assumed to be free of noncardiac life-
threatening morbidities. There were neither explicit indications
nor contraindications for anticoagulation. Second, we assumed
that patients with AVR who experienced major bleeding contin-
ued to receive oral anticoagulant therapy because studies have
shown that the risks of thromboembolism in patients with
mechanical valves who are not on anticoagulant therapy exceed
the risks of recurrent bleeding in those receiving anticoagulation
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went reoperation for valve thrombosis had the initial mechanical
valve replaced by a new valve.
All model input variables, their ranges, and sources are noted
in Table 1. The Egypt-based age-standardized mortality rate was
obtained from the World Health Statistics [15]. The excess mortal-
ity rate was added to the population-based mortality rate in the
model. This excess mortality rate was obtained from a three-
center comparison of 1-year mortality outcomes between trans-
catheter aortic valve implantation and surgical AVR [12]. The risk
for reoperation was obtained from two clinical trials of 211 and 394
patients with AVR who were randomized to receive either tissue or
mechanical valves [16,17]. The probability of death with reopera-
tion was obtained from a decision analysis that compared the
tissue and mechanical valves in patients with AVR [9]. This
probability was calculated using a multivariate logistic regression
equation that was adjusted to the age of 50 years from the above-
mentioned source [9,18]. The risk of major bleeding, the probability
of major bleeding resulting in death, the thromboembolic risk after
AVR, the permanentmorbidity after thromboembolism or bleeding
complications, and the mortality after thromboembolism were
derived from a large study (1608 patients) that determined the
incidence of complications of oral anticoagulant therapy in
patients with mechanical heart valves [19]. We assumed that the
transition probabilities from the recovery state to the health states
of reoperation, bleeding, and thromboembolism were the same as
those for patients in the “reoperation” state.
Relative risk reduction (RRR) and relative risk increase values
for the combined use of warfarin and 100-mg aspirin were
obtained from published data based on a meta-analysis of
randomized trials comparing warfarin plus aspirin and warfarinTable 1 – Model input variables.
Parameter Base case
Probabilities*
Recovery - Bleeding 0.027
Recovery - Reoperation 0.004
Population-based mortality 0.003
Recovery - Death (1st 30 d) 0.071
Recovery - Death (after 1 mo) 0.169
Recovery- Thromboembolism 0.007
Permanent morbidity after 0.67
thromboembolism 0.044
Thromboembolism - Death 0.22
Permanent morbidity after bleeding complication
Bleeding- Death 0.122
Reoperation- Death 0.000013
Utility in recovery state 0.668
Utility in reoperation state 0.45
Utility in bleeding state 0.54
Cost of reoperation event ($) 7414
Cost of bleeding event ($) 2116
Cost of thromboembolism event ($) 1534
Relative risk reduction of thromboembolism (%) 19
Relative risk increase of bleeding (%) 3.2
Relative risk reduction of mortality (%) 10
* Transition probabilities are shown as annual probabilities (which can b
tp1¼1−(1−tpt)1/t.
where tp1 is 1-mo transition probability and tpt is overall probability overalone (hereafter referred to as “warfarin”) in patients with
mechanical heart valves (Table 1) [20]. RRR is deﬁned as the
difference in event rates between two groups, expressed as a
proportion of the event rate in the control group, while relative
risk increase is the proportional increase in rates of bad outcomes
between experimental and control patients in a trial [21]. RRRs for
each end point in the published data were manually calculated
by dividing the absolute risk reduction by the pooled event rates
for each corresponding control group. It was also assumed that
the RRR in the thromboembolism state was identical to that of
the patients who experienced valve thrombosis and proceeded to
the reoperation state.
Outcomes
The outcomes of the two strategies were measured in terms of
quality-adjusted life-years (QALYs). This generic measurement
weighs the length of life by the quality of life a patient experi-
ences while in a speciﬁc health state. QALYs combine both
morbidity and mortality into a single parameter. The quality-of-
life measures that were incorporated into the model were derived
from a Bayesian Markov model that was developed to compare
the cost-effectiveness of patient self-management and physician
management of long-term anticoagulation therapy from the
perspective of Canadian health care payers [7].
A baseline quality-of-life value for patients without an event
or recovery after any event was obtained from a systematic
review that was based on clinical outcome data regarding the
clinical effectiveness and cost-effectiveness from different stud-
ies of the management of long-term oral anticoagulation therapy
that compared the self-testing and self-management of oralRange Data source
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Because estimates of the patient utilities of reoperation for valve
thrombosis are lacking, we assumed that the utility for patients
who undergo reoperation was identical to that for patients in the
thromboembolism state from the time of the event until death
based on data from the above-mentioned sources [7,23]. Because
the validity and reliability of these reported QALYs are untested,
these estimates were allowed to vary over a wide range in the
sensitivity analyses.
Costs
The direct medical care costs of reoperation, bleeding, and
thromboembolism events from the perspective of the medical
provider were obtained from four top-rated cardiology hospital
databases (Table 2) and supplemented with the information that
was available from the authors’ institutions. This secondary
research method provided the best available evidence for the
valuation of health service resources in terms of their unit costs.
The unit costs were calculated by subtracting the proﬁt margin
and sales taxes of each hospital from the hospital charges. No
capital costs were included. Cost data for the base case represent
the average cost of the four top-rated cardiology governmental
hospitals under the public scheme to reﬂect the actual circum-
stances in Egypt. A macrocosting approach was used to deter-
mine the costs. Given the very low costs of both warfarin and
aspirin, the costs of these drugs were not included in the cost
analysis. We assumed that there would be no difference in
resource use for anticoagulation follow-up across strategies in
standard practice (i.e., warfarin was used in both strategies).
Thus, costs for the follow-up visits were not included in the
model. Local currency conversions to US $ were performed using
the purchasing power parity rate [24]. All costs were reported in
US $ for the ﬁnancial year of 2013.
Sensitivity Analysis
To test the stability of our results across variations in input
model parameter estimates, we performed various one-way
sensitivity analyses as recommended by the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS): ISPOR Task
Force report [25]. The robustness of the model-to-model struc-
tures and assumptions was tested with one-way sensitivity
analyses of the estimates of clinical parameters, different time
horizons, health state utilities, costs of reoperation, bleeding, and
thromboembolism, and discount rates for costs and health
effects. The ranges of assumptions tested in our sensitivity
analyses increased as the data on which we based our assump-
tions increased in uncertainty. All model inputs were varied
through conﬁdence intervals or reasonable ranges that weredetermined on the basis of different published sources. All
analyses were performed using Microsoft Excel 2010.Results
The total costs of the two strategies and the corresponding
outcomes as experienced QALY values were recorded. The results
of the analyses are expressed as incremental cost-effectiveness
ratio. The incidences of reoperation over the 5-year time horizon
were 0.09% in the warfarin group and 0.08% in the warfarin plus
aspirin group. The incidences of bleeding were 0.66% in the
warfarin group and 0.69% in the warfarin plus aspirin group.
Thromboembolisms occurred less frequently in the warfarin plus
aspirin group (warfarin group, 0.21%; warfarin plus aspirin group,
0.16%). Similarly, mortality was lower in the warfarin plus aspirin
group (warfarin group, 8.5%; warfarin plus aspirin group, 7.7%).
Across the overall population, the total QALYs of the warfarin
plus aspirin group were estimated to be 1.1616 compared with
1.1199 for the warfarin group, which resulted in a difference of
0.0416 QALYs. The total costs for the warfarin plus aspirin group
and the warfarin group were US $307.33 and US $315.25, respec-
tively (the difference was US $7.92). These costs yielded an
incremental cost-effectiveness ratio of 190.38 for the warfarin
plus aspirin group. Thus, the combined therapy strategy was
dominant (i.e., more effective and less costly). Table 3 provides
the total expected costs and health effects from the base-case
analysis.
One-way sensitivity analyses (Figs. 2 and 3) were conducted to
identify the model parameters that most strongly affected the
incremental QALYs and costs. These analyses indicated that the
probabilities of transition to both the reoperation and bleeding
states from the recovery state had the greatest effects on
incremental costs. The model parameters with the greatest
Fig. 2 – Results of the one-way sensitivity analysis of the incremental costs. RR, relative risk; RRR, relative risk reduction.
F
r
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utility value in the recovery state.
Given the uncertainty surrounding the point estimates of the
relative risks for these outcomes, a sensitivity analysis using
conﬁdence interval ranges was conducted as described in pub-
lished sources [20]. This analysis revealed no effect on treatment
decision. Extrapolating the time horizon of the analysis to 10
years resulted in a gain in QALYs and negative incremental costs
for the combined therapy, which seemed to be driven by the
trend toward decreased mortality in patients who were treated
with the combined therapy. The base-case analysis of the present
study used the average costs for the four top-rated cardiology
governmental hospitals. Sensitivity analysis using the uncer-
tainty ranges estimated from the lowest and highest cost values
for the four top-rated cardiology governmental hospitals (Table 1)
did not alter the conclusions we have reached. The robustness of
the model to changes in quality of life within reasonable ranges
determined from published sources was also explored [26].
Sensitivity analysis of the model results did not alter the
conclusions reached on the basis of other analyses.
When different commonly used discount rates for both health
effects and costs that ranged from 2% to 6% were applied, no
major effects on results were found. Treatment decision was notig. 3 – Results of the one-way sensitivity analysis of the increme
isk reduction.signiﬁcantly affected by other values over their clinical ranges
(Table 1).Discussion
The initiation of antiplatelet plus anticoagulant therapy is likely
to improve the management of patients with prosthetic heart
valves in developed countries, but the most important unmet
need and potential for beneﬁt from these therapies is in devel-
oping countries in which a massive and rapidly increasing
burden of valvular heart disease exists [27]. The results of the
model in this study demonstrate that the combined use of
warfarin and 100-mg aspirin is more effective and less costly
than warfarin alone and should be advocated for patients with
mechanical aortic heart valve prostheses. Interestingly, the
warfarin plus aspirin group exhibited a small gain in QALYs
compared with the warfarin group. Moreover, the costs associ-
ated with warfarin plus aspirin were lower than those associated
with warfarin alone; therefore, the combined use of warfarin and
aspirin is the dominant treatment strategy.
The strength of our model is the use of relative risk data from
a meta-analysis of nine RCTs that include trials that werental QALYs. QALY, quality-adjusted life-year; RRR, relative
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addition, the incorporation of quality-of-life issues may be
important for clinical decisions from the perspective of medical
providers who seek to improve their patients’ lives. The epide-
miologic parameters portion of our analysis is supported by
publications of RCTs of patients with mechanical valves [16,17].
The present study is the ﬁrst to incorporate a decision analysis
approach that compared the cost of complications and the cost-
effectiveness of warfarin plus aspirin versus warfarin alone in
patients with mechanical aortic heart valve prostheses because
cost-effectiveness analyses of the combined use of warfarin and
aspirin are lacking in Egypt and a debate exists between physi-
cians regarding the costs of potential complications.
In our analysis, we explicitly accounted for model input
uncertainties by assigning conﬁdence intervals and plausibility
ranges based on published sources to the quality-of-life, relative
risk, and epidemiologic parameters in the model. This procedure
allowed us to perform one-way sensitivity analyses that revealed
that these factors did not affect our results. In our base case, the
average costs of the four top-rated cardiology hospitals were
used. For this reason, the results of our analysis may seem to be
limited to patients who are treated in leading cardiology hospi-
tals in which treatment costs are typically higher than those of
other hospitals in rural areas. Nevertheless, a sensitivity analysis
using lower rates did not lead to a qualitatively different con-
clusion, which increases the credibility of our analysis. To assess
the inﬂuences of other model structures and assumptions on the
cost-effectiveness estimates, one-way sensitivity analyses of
various parameters were performed. These various sensitivity
analyses did not result in qualitatively different results, and the
model proved to be rather robust. The dominance of the com-
bined therapy versus warfarin only in our model and its robust-
ness in the sensitivity analysis suggest that the combined
therapy with warfarin and aspirin should be preferred by the
decision makers in Egypt.
The analysis of the present study has several limitations that
should be noted. The risk of prosthetic valve endocarditis was not
included because of the low rate (o1% at year one) of this
complication [28]. Similarly, the incorporation of reoperation
and bleeding into one health state is uncommon in contemporary
practice and was not incorporated into the baseline model [26].
The rate of thromboembolism on reoperation was assumed to be
identical to that for patients in the recovery state because of the
absence of reliable data regarding the rate of occurrence of this
event. Another potential limitation, quality-of-life values used in
the model were transferred from the Canadian population
because we have no outcome data available regarding quality-
of-life values for the Egyptian population. Certain elements of
cost-effectiveness studies are transferable. It was based on four
steps that consider data availability and methods for adjusting
cost-effectiveness information to a particular jurisdiction [29]. It
should also be noted that the incorporation of several simplifying
assumptions into the model is a weakness, but this weakness
was overcome by the sensitivity analyses that encompassed wide
ranges of parameter values.
There are other limitations that need to be considered when
assessing the relative generalizability of this study. First, we
adopted the perspective of a medical provider and not a societal
perspective and thus excluded indirect costs and out-of-pocket
direct costs incurred by the patient. Accounting for these costs
would likely increase the superiority of the warfarin plus aspirin
strategy because increases in QALYs will lead to reduced absen-
teeism, increased productivity and recovery, and reduced direct
nonmedical costs associated with the follow-up. Second, the
analysis was primarily based on effectiveness data from a
meta-analysis of RCTs that compared the combined use of
warfarin and aspirin to warfarin alone in patients aged between50 and 60 years with mechanical aortic valve prostheses. Thus,
the ﬁndings cannot easily be generalized to more complex
patients including those with risk factors, young adults, and
elderly patients. Finally, 16 published articles in English were
identiﬁed by our electronic search, but we may have omitted
some important information that could have been recovered
from non-English articles.
The main drivers of the cost-effectiveness of combined
therapy in this model was the reduced numbers of thromboemb-
olisms and the reduced mortality rates that occurred among the
warfarin plus aspirin groups in the previously performed RCTs.
This combined therapy strategy will potentially be applicable to
other settings in Egypt because there are no major differences in
clinical practices between rural and urban areas; thus, combined
therapy will lead to substantial savings in health care system
resources.Conclusions
The present study is the ﬁrst cost-utility analysis that addresses
both the clinical and the economic implications of combined
therapy from the perspective of Egyptian medical providers. This
study concluded that the combined use of warfarin and aspirin is
dominant to the use of warfarin alone for patients with mechan-
ical aortic valve prostheses. Our ﬁndings will help inform health
care decisions regarding the allocation of health care system
resources to improve the health of the Egyptian population. For
those clinicians and patients who choose to focus on minimizing
thromboembolic risk, these results suggest that the combined
therapy offers the best protection and reduced costs because this
well-established antithrombotic treatment improves the quality
of patient care and reduces the overall costs. Whether this
combined therapy is cost-effective in certain subgroups with
additional risk factors needs to be addressed in future studies.
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